At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Randomized, Controlled Trial Evaluating the Effects of Early High-Dose Cryoprecipitate in Adult Patients With Major Trauma Hemorrhage Requiring Major Hemorrhage Protocol (MHP) Activation
In Brief
A Phase 3 clinical trial evaluating Cryoprecipitate, Red Blood Cells, and 3 other interventions for Trauma Injury. Completed, enrolled 1,604 participants across 25 sites in 2 countries.
Detailed Summary
The purpose of this trial is to compare standard of care (SOC) massive transfusion protocol to SOC massive transfusion protocol plus early use of cryoprecipitate (within 90 minutes of emergency department arrival).
Study Details
Timeline
Interventions
Cryoprecipitate is a blood product high in fibrinogen. The Cryoprecipitate will be given with 90 minutes of emergency department arrival. Cryoprecipitate dose will be 3 pools (equivalent to 15 single units).
RBCs are utilized as part of the Massive Transfusion protocol for hemorrhage control.
Plasma is utilized as part of the Massive Transfusion protocol for hemorrhage control.
Platelets are utilized as part of the Massive Transfusion protocol for hemorrhage control.
Whole Blood is utilized as part of the Massive Transfusion protocol for hemorrhage control.